Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-64417184 600 · 1 trial · 1 indication
The relative bioavailability based on Cmax, AUC(0last), and AUC(0-infinity) will be estimated as 100\*Test/Reference where Test is tablet formulation of JNJ-64417184 and Reference is suspension formulation of JNJ-64417184 administered orally in a fasted state.
| Arm | Type | Description |
|---|---|---|
| Group 1: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 milligram (mg) oral tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg oral tablet in fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted condition on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 2: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg oral tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 3: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 4: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 5: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Group 6: JNJ-64417184 | EXPERIMENTAL | Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period. |
| Name | Type | Description |
|---|---|---|
| JNJ-64417184 600 (Oral Tablet Formulation) | DRUG | Participants will receive 600 mg of JNJ-64417184 as oral tablet. |
| JNJ-64417184 (Oral Suspension Formulation) | DRUG | Participants will also receive JNJ-64417184 600 mg as oral suspension. |
Inclusion Criteria: * Healthy on the basis of physical examination, medical and surgical history, and vital signs performed at screening. If there are abnormalities, the participant may be included only if the investigator judges the abnormalities to be not clinically significant or to be appropria...
JNJ-64417184 600 is an investigational small molecule being developed by Johnson & Johnson (JNJ). It is currently in Phase 1 clinical development for use in healthy participants. The drug is being studied to assess its relative oral bioavailability and the effect of food on its absorption.
The molecular target of JNJ-64417184 600 has not been disclosed in available clinical trial information. The drug is a small molecule, but its specific mechanism of action is not publicly detailed in the current development data.
JNJ-64417184 600 is developed by Johnson & Johnson, a multinational pharmaceutical company traded on the NYSE under the ticker JNJ. The company is conducting clinical trials to evaluate the drug's pharmacokinetics in healthy volunteers.
JNJ-64417184 600 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The single Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
JNJ-64417184 600 has one completed clinical trial, NCT03952507, titled 'A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants.' This Phase 1 study enrolled 18 healthy adults in the United States and was controlled but not double-blinded.
JNJ-64417184 600 is a specific dosage form or strength of the investigational drug JNJ-64417184. The clinical trial NCT03952507 refers to the drug as JNJ-64417184, and the '600' designation likely indicates a 600 mg dose or formulation being studied.